Mark is an experienced bio-pharmaceutical professional with a 20 year trajectory in business development, business building, R&D management and strategy. Earlier in Mark’s career he was a research scientist for almost a decade, both in academia and biotechnology, before moving into business.
As Head of Corporate Development at Esteve Mark oversaw the development of joint ventures, licensing transactions (both in and out) and supported all M&A opportunities. Milestones in Mark’s career at Esteve include the establishment of Esteve-Teijin Healthcare, a new entity in the Spanish market to deliver Home Respiratory Therapy, the planning of a VC-backed spinout for Esteve’s pipeline of Gene Therapeutics and the signing of a 3-asset outlicensing deal, the largest such deal in Esteve’s history. Most recently he was coordinating the pre-launch activities of Esteve’s proprietary acute pain product (CTC), including all BD activities related to the product. Mark’s experience in Ophthalmology comes from the development of an expansion strategy in the field that included key enabling transactions to secure portfolio.
Prior to Esteve Mark was an Associate Principal with McKinsey and Company in New York. As a member of McKinsey’s Pharmaceutical and Medical Product Practice Mark had a focus on R&D strategy and portfolio management, serving senior management at top tier pharmaceutical, specialty pharmaceutical and biotechnology companies.
Mark has a BA in Biochemistry from the University of Oxford and a DPhil from the Sir William Dunn School of Pathology also at the University of Oxford. Postdoctoral research was carried out at Memorial Sloan Kettering Cancer Center in New York.